Wet Age-Related Macular Degeneration (AMD) – Market Access and Reimbursement Insights Report – 2025

Wet Age-Related Macular Degeneration (AMD) Market Access and Reimbursement Insights

Thelansis’s “Wet Age-Related Macular Degeneration (AMD) Market Access and Reimbursement Insights Report – 2025″ provides comprehensive payer insights on the current and evolving market access and reimbursement environments for branded and emerging drugs in the indication. Our team understands the criticality of payer research and insights generation, as well as their importance during drug development, pre-market launch strategy, and post-marketing activities.

Wet Age-Related Macular Degeneration (AMD) Overview

Wet Age-Related Macular Degeneration (AMD), also known as neovascular or exudative AMD, is a progressive retinal disorder characterized by the abnormal growth of blood vessels beneath the macula, the central portion of the retina responsible for sharp, detailed vision. These fragile vessels tend to leak blood and fluid, leading to macular scarring and rapid deterioration of central vision, often manifesting as visual distortions, blind spots, or difficulty recognizing faces and reading. Although it accounts for only 10–15% of AMD cases, wet AMD is responsible for the majority of severe vision loss associated with the disease. It typically evolves from the dry form of AMD and can progress swiftly if untreated. Diagnosis relies on imaging modalities such as optical coherence tomography (OCT) and fluorescein angiography, which help visualize fluid accumulation and vascular changes. Treatment has advanced significantly with intravitreal anti-VEGF therapies that inhibit vessel growth and leakage, offering the potential to stabilize or even improve vision if initiated promptly.

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by surveys* and interviews with payers (e.g., pharmacy directors / medical directors from managed care organizations with Medicare and/or Commercial plans in the United States). If required, primary market research with physicians is also done to understand the impact of reimbursement environment on treatment decisions for current and emerging brands.

*Survey and interview discussion guide are customized based on client requirements

Deliverables format:

• PowerPoint presentation

*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.

Key business questions answered:

• Market access and reimbursement for current therapies
• Coverage on plans
• Market access restrictions
• Rebates and contracting
• Factors influencing formulary access
• HEOR requirements and influence, etc.
• Expected market access and reimbursement for key emerging therapies
• Level of awareness
• Anticipated coverage on plans
• Factors that would improve market access
• Pricing, etc.
• Impact on brand use
• Key factors driving and limiting brand use
• Best and worst performers on market access, etc.
• Evolving environment
• Payer expectations from emerging therapies
• New policies and their expected impact, etc.
• Advise to drug manufacturers and developers

Read more: Wet Age-Related Macular Degeneration (AMD) – Market Access and Reimbursement Insights Report – 2025